▲
STOCKUPSIDE.IO
Analyst Price Target Intelligence
← Full Rankings
← Back to rankings
Ranked #1558 by analyst upside · 2026-09-27
BMRN
BioMarin Pharmaceutical Inc.
Healthcare · Market Cap $12B · P/E 167.4x
ANALYST PRICE TARGET
+52.0%
implied upside to consensus target
Current Price $60.26
Consensus Target $91.62
Bull Target $124.0
Bear Target $60.0
Analysts Covering 26
ANALYST CONSENSUS - BUY
Strong Buy
6
Buy
13
Hold
7
Sell
0
52-Week Low $49.26
52-Week High $70.98
YTD Return +1.4%
FUNDAMENTALS
Market Cap $12B
P/E Ratio (TTM) 167.4x
Forward P/E 9.1x
EPS (TTM) $0.36
PEG Ratio 0.35
Dividend Yield N/A
Revenue (TTM) $3.4B
Profit Margin 2.1%
52-WEEK RANGE
52-Week Low $49.26
52-Week High $70.98
Current Price $60.26
Bear Target $60.0
Bull Target $124.0
● Now $60.26 ● Target $91.62
TRADING DATA
Avg Volume 1.9M
YTD Return +1.4%
Analyst Count 26
Consensus Buy
Upside to Target +52.0%
Last Updated 2026-09-27

ANALYST SUMMARY

BioMarin Pharmaceutical Inc. (BMRN) is currently trading at $60.26 with a Wall Street consensus price target of $91.62, implying potential upside of 52.0% over the next 12 months. 26 analysts currently cover BMRN, with a consensus rating of Buy - 73% of analysts rate the stock a Buy or Strong Buy. The most bullish analyst has a price target of $124.0, while the most cautious has a target of $60.0.

BMRN operates in the Healthcare sector with a market capitalisation of $12B. The stock is up 1.4% year-to-date and is currently trading near the upper end of its 52-week range of $49.26 – $70.98.

SIMILAR STOCKS

Other Healthcare stocks with comparable size and valuation.

ICUI +17.2%
ICU Medical, Inc.
$4B · P/E 138.6x · Buy
ALKS +38.4%
Alkermes plc
$7B · P/E 107.5x · Buy
CORT +21.4%
Corcept Therapeutics Incorporated
$13B · P/E 258.0x · Buy
ICLR +7.5%
ICON Public Limited Company
$13B · P/E 265.1x · Buy
RVTY -14.6%
Revvity, Inc.
$17B · P/E 72.3x · Hold

RECENT ANALYST CALLS

Upgrade/downgrade history for BMRN, with each firm's 90-day track record across all stocks we track. See full firm rankings →

HC Wainwright & Co. reit
Neutral → Neutral 2026-09-10 31% win rate (48 calls)
Piper Sandler - Reiterated
Overweight → Overweight 2026-09-01 14% win rate (7 calls)
Jefferies - Reiterated
Buy → Buy 2026-08-31 50% win rate (6 calls)
HC Wainwright & Co. - Reiterated
Neutral → Neutral 2026-08-31 31% win rate (48 calls)
BMO Capital ● Initiated
Outperform → Outperform 2026-08-19 Building track record
HC Wainwright & Co. - Reiterated
Neutral → Neutral 2026-08-18 31% win rate (48 calls)
Piper Sandler - Reiterated
Overweight → Overweight 2026-08-17 14% win rate (7 calls)
Barclays - Reiterated
Overweight → Overweight 2026-08-17 Building track record
HISTORICAL SNAPSHOT

Point-in-time data from StockUpside's daily snapshots. Tracks price, analyst target, upside %, consensus, and analyst count.

Loading…
ANALYST CONVICTION SCORE
48
out of 100
Coverage depth
25/30
Consensus clarity
9/30
Vote unanimity
12/25
Rating stability
2/15

Measures analyst agreement, not fundamental quality. A high score means analysts broadly agree on this call - not that the stock will go up.

See 4,000+ stocks ranked by analyst upside

StockUpside.io tracks analyst consensus price targets across thousands of US-listed stocks, updated every day. The full ranked list is available with a Pro subscription.

View Full Rankings →